Exploring the antioxidant potential of chalcogen-indolizines throughout in vitro assays

Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are highly reactive molecules produced naturally by the body and by external factors. When these species are generated in excessive amounts, they can lead to oxidative stress, which in turn can cause cellular and tissue damage. This damage is known to contribute to the aging process and is associated with age-related conditions, including cardiovascular and neurodegenerative diseases. In recent years, there has been an increased interest in the development of compounds with antioxidant potential to assist in the treatment of disorders related to oxidative stress. In this way, compounds containing sulfur (S) and/or selenium (Se) have been considered promising due to the relevant role of these elements in the biosynthesis of antioxidant enzymes and essential proteins with physiological functions. In this context, studies involving heterocyclic nuclei have significantly increased, notably highlighting the indolizine nucleus, given that compounds containing this nucleus have been demonstrating considerable pharmacological properties. Thus, the objective of this research was to evaluate the in vitro antioxidant activity of eight S- and Se-derivatives containing indolizine nucleus and different substituents. The in vitro assays 1,1-diphenyl-2-picryl-hydrazil (DPPH) scavenger activity, ferric ion (Fe3+) reducing antioxidant power (FRAP), thiobarbituric acid reactive species (TBARS), and protein carbonylation (PC) were used to access the antioxidant profile of the compounds. Our findings demonstrated that all the compounds showed FRAP activity and reduced the levels of TBARS and PC in mouse brains homogenates. Some compounds were also capable of acting as DPPH scavengers. In conclusion, the present study demonstrated that eight novel organochalcogen compounds exhibit antioxidant activity.

Synthetic drives for useful drug molecules through organocatalytic methods

The treatment of various pathological conditions in human beings involves the use of safe and efficacious drug substances. But there are different complications associated with the treatment of various disease states including drug resistance, adverse drug reactions, toxicity, etc. To minimize these problems, there is an urgent need to develop new therapeutics with suitable pharmacokinetic and pharmacodynamic properties. So, the organocatalytic methods are emerged as a potential synthetic tool to accelerate the design of new drug candidates with improved physicochemical and pharmacological properties, selectivity, and efficiency for the treatment of life-threatening diseases. Organocatalytic reactions refer to the chemical reaction that is accelerated by organic catalysts instead of using organometallic catalysts. Organocatalysts are more advantageous in comparison to metallic catalysts because organocatalysts are cost-effective, stable, efficient, non-toxic, readily available, and easy to handle. In addition to this, the organocatalysis method involves an eco-friendly reaction by minimizing the formation of by-products and reducing the chemical hazards. Organocatalysts are categorized into four classes such as Lewis acids, Lewis bases, Bronsted acids, and Bronsted bases. These catalysts are generally involved in various reactions mechanisms such as Aldol reaction, Diels–Alder reactions, Michael Addition and Knoevenagal reactions, etc. The utility of organocatalyst in synthetic chemistry results in the development of medicinally active compounds with diverse structural features.

Synthesis, antioxidant and antitumoral activity of new 5′-arylchalcogenyl-3′-N-(E)-feruloyl-3′, 5′-dideoxy-amino-thymidine (AFAT) derivatives

A new multitarget arylchalcogenyl zidovudine derivative is disclosed. The compounds showed a prominent antioxidant and antitumoral activity with no overt sign of toxicity for in vivo evaluations.